Meyahealth
Home
ENES
HomeGeneticsGeneSLC26A2 gene
Back to Gene

SLC26A2 gene

Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

SLC26A2 gene

The SLC26A2 gene is responsible for transporting sulfate ions, a process critical for the development of healthy cartilage and bone.

Normal Function

The SLC26A2 gene provides instructions for making a protein that transports sulfate ions across cell membranes. This protein is active in many tissues, particularly in developing cartilage—a tough, flexible tissue that forms the skeleton during early development and later covers the ends of bones.

Cartilage cells use these sulfate ions to build proteoglycans, molecules consisting of sugars attached to a protein that give cartilage its rubbery, gel-like structure. Because sulfate is required for proteoglycan production, the SLC26A2 protein is essential for normal cartilage formation.

Health Conditions Related to Genetic Changes

Mutations in the SLC26A2 gene disrupt the transport of sulfate ions, preventing the production of normal proteoglycans and leading to various skeletal disorders:

Achondrogenesis (Type 1B)

This rare, severe disorder is characterized by extremely short limbs, a narrow chest, and a prominent abdomen. Infants with this condition usually die before or soon after birth due to severe disruption of cartilage structure.

Atelosteogenesis type 2

A severe disorder of cartilage and bone development. Affected individuals typically have one mutation that disrupts the protein structure and another that prevents the production of any functional protein.

Diastrophic dysplasia

A disorder of cartilage and bone development with features similar to atelosteogenesis type 2, though generally less severe.

Multiple epiphyseal dysplasia

A disorder primarily affecting the ends of long bones (epiphyses). The recessive form of this condition is caused by SLC26A2 mutations that typically retain some protein function, resulting in milder symptoms compared to other SLC26A2-related skeletal disorders.

Frequently Asked Questions

SLC26A2-related skeletal disorders are often diagnosed based on characteristic physical features and skeletal X-rays. For severe forms like achondrogenesis, diagnosis can occur prenatally through ultrasound imaging, which may reveal extremely short limbs, a narrow chest, or other skeletal abnormalities. Genetic testing for SLC26A2 mutations can confirm the diagnosis both prenatally and postnatally, providing a definitive answer.
The severity of SLC26A2-related conditions varies significantly. Achondrogenesis Type 1B is the most severe, often lethal shortly after birth due to extreme skeletal disruption. Atelosteogenesis Type 2 is also severe, causing significant bone and cartilage abnormalities. Diastrophic dysplasia is less severe than achondrogenesis but still involves significant skeletal issues like short stature, joint contractures, and clubfoot. Multiple epiphyseal dysplasia (recessive form) is generally the mildest, primarily affecting the ends of long bones and leading to joint pain and early-onset arthritis, with less impact on overall stature.
Management is primarily supportive and multidisciplinary, focusing on alleviating symptoms and improving quality of life. This can include orthopedic surgeries to correct deformities or address joint issues, physical therapy to maintain mobility and strength, and pain management. For conditions like diastrophic dysplasia, interventions may include bracing, casting, or surgery for clubfoot and scoliosis. Regular monitoring by specialists, including orthopedists and geneticists, is crucial.
Mutations in the SLC26A2 gene typically follow an autosomal recessive inheritance pattern. This means that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition. Parents who are carriers (have one mutated copy) usually do not show symptoms. For family planning, if both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two mutated copies and be affected. Genetic counseling can provide detailed risk assessments and discuss options like prenatal diagnosis or preimplantation genetic diagnosis.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.